Nevro Corp NVRO
We take great care to ensure that the data presented and summarized in this overview for NEVRO CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVRO
View all-
Armistice Capital, LLC New York, NY3.62MShares$41.3 Million0.71% of portfolio
-
Black Rock Inc. New York, NY3.41MShares$38.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.17MShares$36.2 Million0.0% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO2.8MShares$31.9 Million0.5% of portfolio
-
Fred Alger Management, LLC New York, NY2.08MShares$23.8 Million0.15% of portfolio
-
Glenn Welling Engaged Capital LLC | Newport Beach, Ca1.89MShares$21.5 Million4.77% of portfolio
-
Braidwell LP Stamford, CT1.78MShares$20.3 Million0.83% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.15MShares$13.2 Million0.01% of portfolio
-
State Street Corp Boston, MA1.09MShares$12.4 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD1.07MShares$12.1 Million0.4% of portfolio
Latest Institutional Activity in NVRO
Top Purchases
Top Sells
About NVRO
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
Insider Transactions at NVRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 24
2024
|
Kevin R Thornal President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
24,233
-8.47%
|
$290,796
$12.51 P/Share
|
|
Apr 11
2024
|
D Keith Grossman |
SELL
Payment of exercise price or tax liability
|
Direct |
3,986
-1.85%
|
$51,818
$13.12 P/Share
|
|
Apr 04
2024
|
Kashif Rashid SVP, Corp Dev and CLO |
SELL
Payment of exercise price or tax liability
|
Direct |
479
-0.29%
|
$6,227
$13.21 P/Share
|
|
Mar 31
2024
|
Frank M Fischer |
BUY
Grant, award, or other acquisition
|
Direct |
1,159
+1.98%
|
-
|
|
Mar 31
2024
|
Elizabeth H Weatherman |
BUY
Grant, award, or other acquisition
|
Direct |
1,372
+2.4%
|
-
|
|
Mar 31
2024
|
Michael F Demane |
BUY
Grant, award, or other acquisition
|
Direct |
1,817
+5.19%
|
-
|
|
Mar 31
2024
|
Sridhar Kosaraju |
BUY
Grant, award, or other acquisition
|
Direct |
1,090
+5.57%
|
-
|
|
Mar 11
2024
|
D Keith Grossman |
SELL
Payment of exercise price or tax liability
|
Direct |
2,184
-1.0%
|
$30,576
$14.99 P/Share
|
|
Mar 07
2024
|
Roderick H. Mac Leod Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,136
-4.83%
|
$107,040
$15.32 P/Share
|
|
Mar 07
2024
|
Roderick H. Mac Leod Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
84,326
+36.32%
|
-
|
|
Mar 07
2024
|
Greg Siller Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,893
+32.46%
|
-
|
|
Mar 07
2024
|
Kashif Rashid SVP, Corp Dev and CLO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,045
-4.06%
|
$105,675
$15.32 P/Share
|
|
Mar 07
2024
|
Kashif Rashid SVP, Corp Dev and CLO |
BUY
Grant, award, or other acquisition
|
Direct |
84,326
+32.71%
|
-
|
|
Mar 07
2024
|
Kevin R Thornal President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
150,581
+34.47%
|
-
|
|
Mar 07
2024
|
Richard B. Carter Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,706
-5.07%
|
$40,590
$15.32 P/Share
|
|
Mar 07
2024
|
Richard B. Carter Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,866
+24.02%
|
-
|
|
Mar 04
2024
|
Kashif Rashid SVP, Corp Dev and CLO |
SELL
Payment of exercise price or tax liability
|
Direct |
425
-0.47%
|
$5,950
$14.51 P/Share
|
|
Mar 04
2024
|
Kashif Rashid SVP, Corp Dev and CLO |
BUY
Grant, award, or other acquisition
|
Direct |
743
+0.82%
|
-
|
|
Mar 04
2024
|
Richard B. Carter Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
125
-0.34%
|
$1,750
$14.51 P/Share
|
|
Mar 04
2024
|
Richard B. Carter Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
212
+0.58%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 601K shares |
|---|---|
| Open market or private purchase | 7.5K shares |
| Bona fide gift | 80K shares |
|---|---|
| Payment of exercise price or tax liability | 87.4K shares |